Income investors chasing high yields often lock in the slowest raises. Instead, businesses that start below the market yield but push the payout higher every year are ideal.

Beam Therapeutics is reaffirmed as a long-term buy, with significant upside expected around 2028–2029 as BEAM-302 advances.

The most consequential APAC biopharma deal of 2026 is Sun Pharma's all-cash agreement to buy Organon, which Sun describes as ...

View MSC Industrial Direct Co., Inc. Class A MSM stock quote prices, financial information, real-time forecasts, and company news from CNN.

Q2 starts at Rs. 48.89 Lakh, GLA Class starts at Rs. 41.51 Lakh. Compare mileage, engine, safety & features to see which ...

LuxExperience Q4 FY2026 sales rose 7.6% as adjusted EBITDA margin reached 2.1%. Management guided FY2027 growth to mid-to-high single digits.

A 9.2% jump to $61.62 adds roughly $7 billion of market value in a single session, an outsized day for an $81.8 billion enterprise hardware name that rarely moves like this. Watch whether it holds ...

A major bipartisan bill to overhaul college athletics nationwide passed the Senate, clearing a key hurdle and setting up a ...